The overall goal of this project is to identify autoantibody biomarkers in sera that can be readily used for the early detection of cancer. Antibodies are induced by tumor-specific alterations in protein expression, mutation, degradation, or localization, with high specificity. We have developed a novel programmable protein microarray technology (NAPPA), which uses printed cDNA encoding tumor antigens that are translated in vitro. We have been funded for the past four years as an EDRN Biomarker Development Laboratory to develop NAPPA as a clinical research tool and to employ it for the detection of autoantibody biomarkers for breast cancer, and have screened over 700 sera and identified 32 novel breast and 23 ovarian biomarkers that have undergone blinded validation studies. Here, we propose to increase the feature density of NAPPA arrays in order to accommodate the increasing size of our cDNA collection, which now approaches 10,000 unique genes (Aim 1) and to develop a method for producing glycoproteome arrays (Aim 2). Both of these methods will enhance autoantibody biomarker discovery by increasing the number and quality of the antigens screened.
Aim 3 will use the results of Aims 1 and 2 to expand the top breast cancer biomarkers that have been identified to focus on particular subtypes of breast cancer that are more difficult to detect including Her2+ breast cancers, triple-negative (ER-PR-Her2-) breast cancers, and cancers that occur in the setting of high breast density. Association of antibody detection and tumor antigen expression will be explored.
Aim 4 will assess the performance characteristics of the combined set of top breast cancer biomarkers in Phase II studies using sera collected in multicenter clinical studies.
Aim 5 will focus on the utility of these biomarkers to detect disease prior to clinical diagnosis. At the end of these experiments, our goal is to identify autoantibody serum signatures that can be used by EDRN CEVCs in further Phase III independent validation studies for the early detection of breast cancer according to the EDRN biomarker discovery guideline.

Public Health Relevance

In 2008, it is estimated that over 40,000 people will die of breast cancer, and over 500,000 will die of other cancers, with increased morbidity and mortality when cancers are detected at late stages. This project focuses on eariy detection biomarker discovery for breast cancer to complement mammographic screening, with an ultimate goal to reduce overall breast cancer morbidity and mortality.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Patriotis, Christos F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Arizona State University-Tempe Campus
Organized Research Units
United States
Zip Code
D'Souza, Gypsyamber; Gross, Neil D; Pai, Sara I et al. (2014) Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 32:2408-15
Yu, Xiaobo; Woolery, Andrew R; Luong, Phi et al. (2014) Copper-catalyzed azide-alkyne cycloaddition (click chemistry)-based detection of global pathogen-host AMPylation on self-assembled human protein microarrays. Mol Cell Proteomics 13:3164-76
Wallstrom, Garrick; Anderson, Karen S; LaBaer, Joshua (2013) Biomarker discovery for heterogeneous diseases. Cancer Epidemiol Biomarkers Prev 22:747-55
Festa, Fernanda; Steel, Jason; Bian, Xiaofang et al. (2013) High-throughput cloning and expression library creation for functional proteomics. Proteomics 13:1381-99
Yu, Xiaobo; Wallstrom, Garrick; Magee, Dewey Mitchell et al. (2013) Quantifying antibody binding on protein microarrays using microarray nonlinear calibration. Biotechniques 54:257-64
Qiu, Ji; LaBaer, Joshua (2011) Nucleic acid programmable protein array a just-in-time multiplexed protein expression and purification platform. Methods Enzymol 500:151-63
Yang, Chuanwei; Hayashida, Tetsu; Forster, Nicole et al. (2011) The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res 71:937-45
Anderson, K S; Wong, J; D'Souza, G et al. (2011) Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer 104:1896-905
Anderson, Karen S; Sibani, Sahar; Wallstrom, Garrick et al. (2011) Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 10:85-96
Sibani, Sahar; LaBaer, Joshua (2011) Immunoprofiling using NAPPA protein microarrays. Methods Mol Biol 723:149-61

Showing the most recent 10 out of 19 publications